Blackpool CCG Medicines Optimisation

Blackpool CCG Medicines Optimisation

Medicines play an important part in promoting well-being, preventing ill-health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines Management can be defined in several ways:

The clinical, cost-effective, safe and secure handling of medicines
A system of processes and behaviours that determines how medicines are used by the NHS and patients
Enabling people to make the best possible use of medicines
Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s Medicines Management team on 01253 951306 or email blackpool.medicinesoptimisation@nhs.net


 

Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

Prescribing guidance

NameSizeHits
Axial-Spondyloarthritis-pathway-Version 37 KB22
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB29
Chronic-Non-cancer-Pain-Guidelines-Version 1.2 MB25
Colomycin prescribing information sheet Non CF indications. 0.2 MB9
Constipation-Pathway-Version 0.7 MB25
Diabetes - Algorithm for antihyperglycaemic therapy in adults with type II Diabetes 0.6 MB26
Diabetes - BG meters and test strips Type-2-Diabetes 0.5 MB60
Diabetes - Glucagon Like Peptide Contract 0.2 MB27
Diabetes - Home Monitoring of Blood Glucose Levels Guidelines 0.3 MB22
Diabetes-self-management-contract 0.5 MB40
Edoxaban Prescribing Tip 68 KB38
Erectile-Dysfunction-Guideline-Version 1.0 MB27
Gastroenterology-Biologics-Pathway-Version 0.4 MB25
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB27
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB40
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB5
Headache Management Guideline for Adults 0.7 MB12
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB23
Interim Gender Dysphoria protocol 0.6 MB16
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB34
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB15
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB43
Neuropathic Pain Guidance (Version 1.2) 0.9 MB18
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB28
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB18
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB26
Primary Care Good Prescribing Guide 1.0 MB36
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB27
Psoriasis-LMMG-Biologic-and-High-Cost-Drug-Commissioning-Pathway-Version 0.8 MB26
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB28
RA-High-Cost-Drugs-Pathway-v 0.2 MB25
Restless Legs Syndrome guidelines 0.3 MB5
SIP Feeds 0.1 MB26
Wound care formulary 8.2 MB27

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place (October 2018):

  • Fencino (Fentanyl) – Started 1 October 2018
  • Firmagon (Degarelix) – Started 1 September 2016
  • GlucoRx – Started 1 July 2018
  • Januvia (Sitagliptin)  – Started 1 September 2018
  • Lixiana (Edoxaban) – Started 1 October 2018
  • Seretide (Fluticasone / Salmeterol) – Started 1 January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started 1 October 2018

Last updated on 14 January 2019 at 11:28 by communications manager